Back to top

From Ryan White to global aid, a new congressional majority could influence funding, policy and oversight—but it won’t automatically reverse White House budget cuts or policy restrictions

The past two years have witnessed massive upheavals in HIV funding, programs and policies wrought by the Trump 2.0 administration while a Republican-controlled Congress has looked on, largely supporting the Trump agenda. 

 

For people living with and affected by HIV, both here in the United States and abroad, the November 3 midterm elections will determine if Congress takes a different course, using its spending and oversight powers to challenge these changes. The stakes include access to care, treatment and housing; funding of HIV research, clinical trials, prevention and aid in the global fight against HIV.

 

Massive cuts to the U.S. global assistance programs USAID and PEPFAR, which worked hand in hand, have led to serious rollbacks in HIV treatment and prevention in poor nations worldwide. 

 

Meanwhile, the Centers for Disease Control and Prevention (CDC) has seen major reductions in spending, cuts to its workforce and changes in public health policies at the hands of the administration, affecting HIV surveillance and prevention and putting progress to end the epidemic in the U.S. at risk of reversal.

 

Republicans have repeatedly eyed cutbacks to the Ryan White CARE Act (RWCA)—the country’s last-resort funder for people living with HIV who have no other health coverage—but some lawmakers (mostly Democrats, with some Republican allies) have pushed back, and activists and groups such as the Save HIV Funding Campaign have called out the proposed cuts. 

 

For over a decade, funding RWCA’s AIDS Drug Assistance Program (ADAP), which pays for meds and provides assistance for the health plans that cover them, has remained relatively flat—about $900 million annually—while demand and expenses have increased. Ryan White provides ADAP money to the individual states, which are then responsible for administering their own program. A growing number of states are starting to trim back the eligibility or the scopes of their RWCA-funded programs. This year, Florida made headlines with cuts to its ADAP, restricting use of Descovy and even temporarily dropping Biktarvy, the most commonly prescribed HIV medication, from its formulary, as part of the state’s efforts to reduce costs. (The cuts were later largely reversed.)

 

For all these reasons—and many more—the stakes are high in the midterm elections on November 3. As of this writing, it looks as though—due to record low approval ratings for Trump based largely on the ever-rising cost of living and the continuing war with Iran—Democrats are favored to take the House and possibly (although much less likely) even the Senate. 

 

And yet, should Democrats capture both or even one chamber of Congress, it doesn’t mean they can completely undo the Trump/GOP actions of the past two years. 

 

For one thing, in the Senate, the minority party can filibuster (indefinitely delay) a vote on a bill unless a majority of 60 or more senators vote to “invoke cloture” and break the filibuster. And as president, Trump can always veto whatever bill Congress passes that he doesn’t like. Moreover, it’s highly unlikely that Democrats will gain the two-thirds majority in both chambers needed to override a veto.

 

“A change in congressional control does not automatically reverse administration policy,” explains Matthew Rose, director of public policy and government affairs for TruEvolution, a California HIV/AIDS services nonprofit. “Many administration actions are undertaken through executive orders, agency regulations, guidance, enforcement decisions and other administrative authorities. Those actions do not automatically disappear because control of Congress changes.”

 

These caveats mean that, even if Democrats take both chambers, the next two years “probably will be a stalemate, with not much policy getting moved,” says Maxx Boykin, campaign manager for the Save HIV Funding Campaign.

 

Nonetheless, says Rose, with majorities in one or both chambers, Democrats would have the opportunity to respond to everything the Trump administration does “with legislation, appropriations, oversight, investigations, confirmation authorities where applicable and other institutional tools, but the effectiveness of those tools depends on the particular action and applicable law.”

 

In other words, Democrats would have significant tools to push back on the administration’s past two years of running roughshod over Congress, such as refusing to release congressionally appropriated funding for anything it doesn’t like. The current Republican leaders in Congress have almost entirely demurred from pushing back.

 

Another uncertainty is whether Trump would be willing to negotiate with Democratic leaders in Congress, especially if they are joined by some Republicans on key issues.

 

The 22nd Amendment limits a president to two terms or 10 years (if taking office from their predecessor). Despite his repeated jokes and comments, Trump will not be able to run again in 2028. However, it is uncertain what he will do to leave the door open for the Republican Party or a chosen successor.’’ 

 

With all that in mind, POSITIVELY AWARE talked with Boykin, Rose and other experts in the field about what’s most at stake for HIV issues in the upcoming elections. Everyone noted the need for people in the HIV community to vote and, if they can, help get out the vote. You can find your state’s voter registration deadline here. Most states’ registration deadlines fall between early and late October, though some states allow you to bypass standard deadlines through same-day registration.

 

f you want to help get out the vote in your state, contact the statewide office of the party of your choice, Democratic or Republican, which can connect you to opportunities. Also check out this midterms toolkit put together by Positive Women’s Network-USA.

 

“Elections have consequences,” says Boykin, “and many things are at stake with these upcoming elections related to access to funding—as well as how we see democracy moving forward in this country and how it impacts our ability to live our daily lives and pay our bills.” 

 

The big picture: Who has control?

 

Earlier this year, the White House Office of Management and Budget proposed requiring that all federal grants be reviewed by a panel of political appointees to make sure they “aligned” with Trump’s anti-“woke,” anti-DEI (diversity, equity and inclusion) ideology. The move sparked opposition by some on Capitol Hill and among activists, prompting Congress to add a ban on such a review to the continuing resolution (CR) it passed to fund the government. Both the ban and the CR run through December 11. 

 

But the specter of political overview will still linger when Congress takes up the issue of funding the government beyond December 11. A lame-duck session of Congress after the midterms could attempt to rush through legislation and spending plans before the new Congress is sworn in on January 3, 2027. 

 

“Keeping that [expansion] rule out of play will be paramount,” says Rose. He noted that, were the rule to go into effect, the White House would likely nix funding for anything it saw as promoting “gender ideology and DEI,” which, in the administration’s overbroad view of those terms, could include several streams of HIV-related funding.

 

If Democrats gain more power in Congress, says Rose, “then after the elections, they can say to Republicans, ‘We’re not negotiating [funding the government] with you now because we can rewrite this bill to be better in the new year.’ It’s shutdown leverage.”

 

Educating the newcomers

 

This year, the GOP-led House released a budget proposal that cut $224.9 million from Ryan White’s current funding level of $2.571 billion—a slash of 8.75%.

 

It’s not the first time in recent years that Republicans in the House have tried to cut the program, only to have the Senate block them. Nonetheless, the program has been flat-funded for more than a decade despite ever-rising underlying costs for meds and ACA health plans. That means that more and more states are trimming back what Ryan White offers, and to whom. 

 

Who controls Congress next year could determine whether Ryan White receives the additional $150 million advocates are seeking to help prevent further cuts to ADAP, which accounts for about $900 million (or 35%) of Ryan White’s total budget.

 

“If the Democrats take Congress, we’re more likely to get the funding increase because it falls into their narrative that they’re prioritizing healthcare,” says Rose. “That would take the stress off states at least for another year, even though we’ll have problems again beyond that because we’ll never keep up with medical inflation.”

 

But Rose stresses that, whatever happens in the midterms, advocates and groups like Save HIV Funding will have to lobby hard for that budget increase because next year’s Congress will be full of newcomers “who don’t know our issues”—meaning all the essential programs and services Ryan White provides for people with HIV, from meds and care to transportation, housing and food. 

 

And advocates won’t have to educate just Republicans. Lindsey Dawson, associate director of HIV policy at KFF, a health policy center, says a Democratic majority in Congress doesn’t guarantee more money. “Democrats haven’t increased funding in the past when they had the power to,” she points out. 

 

In other words, even if Democrats gain control, the age-old work of visiting lawmakers to help them understand the importance of Ryan White goes on.

 

Medicaid

 

Under the so-called “One Big Beautiful Bill,” backed by Trump and approved by congressional Republicans last year, Medicaid recipients who became eligible through expansion of the Affordable Care Act (ACA, also known as “Obamacare”) will be required, starting January 1, to show they are spending 80 hours a month in work, school or volunteering. 

 

People with HIV are not among the categorical exemptions to the rule and will have to show medical frailty or severe impairment to be exempted.

 

Experts have calculated that the new rule will knock millions off Medicaid due to failures to properly document proof of work on an ongoing basis—and that could include some of the 40% of people living with HIV who rely on Medicaid. 

 

Even if Democrats win one or both chambers of Congress and try to repeal the rule, they probably still won’t have enough votes to override a Trump veto, says Dawson. But an increase in Democratic power in Congress, plus the immense technological challenges states are predicted to have in tracking work rule compliance, could help lead to targeted delays or bureaucratic tweaks that soften the rule. Democrats in power in Congress would also control committees, leading to oversight hearings into how the rule is being implemented—inquiries that Trump-aligned Republicans likely would not initiate on their own.

 

However, notes Rose, real efforts to repeal the rule may not occur until “Republicans hear from their constituents about the pain” it’s causing them in trying to adhere to the rule, or to lose coverage entirely because of it. Also, a repeal likely would not happen until the U.S has a president who supports it and thus would not veto it.

 

HIV surveillance and prevention 

 

Since the Trump administration and a GOP-led Congress took power in early 2025, they have cut $600 million in HIV prevention and surveillance grants from Democratic-led states and have also stopped giving money directly to nonprofit HIV/AIDS services organizations that historically have been most nimble at providing HIV testing and other services in their communities. Instead, that money has been redirected to state and local health departments to disburse to nonprofits as they choose.

 

Additionally, the House budget proposal released earlier this year calls for a total end to HIV prevention funding through the CDC, leaving in place modest funding through the Ending the Epidemic initiative, which Trump established in his first term and has barely mentioned in his second.

 

Even if Democrats don’t take Congress, it’s likely that the Senate, as it did last year, would prevent such dramatic cuts. But in the wake of what conservatives call the CDC’s poor handling of the COVID pandemic, the agency is generally not popular with Republicans, especially heavily Trump-aligned ones. 

 

More Democratic power in Congress could mean more protection for CDC funding, not just in HIV but overall. It could also mean more robust pushback if and when the White House tries to withhold CDC funding that Congress has already appropriated, which it has already tried to do.

 

Also, with Democratic control, there is somewhat more of a chance that certain current Democratic-led bills to expand free PrEP [HIV prevention] access could get passed, even though they might well face Trump’s veto. 

 

“There’s still bipartisan support” for HIV prevention efforts, says Jeremiah Johnson, executive director of the PrEP-access advocacy group PrEP4All, which supports such bills, “so there’s no reason for us to give up, particularly if Democrats do well in the midterms.”

 

Global aid

 

Since early last year, while the Trump administration has retained some core elements of PEPFAR, the highly successful global HIV/AIDS treatment and prevention program started in 2003 by President George W. Bush, it has been dramatically weakened and reduced in scope. It has banned prevention services like PrEP for all groups except pregnant and breastfeeding women and all but shuttered USAID, the long-standing U.S. aid agency that worked hand in hand with PEPFAR to set up special clinics for vulnerable populations such as LGBTQ+ people, sex workers and people who use drugs.

 

The White House has also held back an estimated $3.1 billion in PEPFAR funding that Congress had approved before Trump took office for the second time.

 

If the Democrats take Congress, not only could they call for increased funding for PEPFAR, they could also have more powerful oversight of the Trump administration’s holding back or delaying funds that have been appropriated by Congress. They could launch formal committee investigations into the Office of Management and Budget, which controls the flow of funds, and they could subpoena administration officials to grill them about funding backlogs.

 

Housing Opportunities for Persons with AIDS (HOPWA)

 

Remarkably, HOPWA, which provides housing assistance and supportive services to low-income people with HIV and to their families, was the only HIV program that saw an increase in funding early this year, with a $24 million bump. But advocates have long said that HOPWA, currently funded at $524 million, needs up to $1 billion to provide housing assistance to more than a fraction of low-income people with HIV who need it.

 

Affordable Care Act subsidies

 

Late last year, the GOP-led Congress allowed the expiration of enhanced subsidies on ACA plans for income-eligible recipients. That has led to up to 3 million people dropping their ACA health coverage because they simply could not afford price hikes as high as $1,000 per month.

 

Democrats initially refused to end the government shutdown last year unless the ACA subsidies were reinstated. But then a handful of moderate Democrats, fearful their constituents would blame them if the government shutdown continued, broke ranks and joined Republicans in passing a bill to end the shutdown. 

 

However, if Democrats take back even one chamber of Congress next year, they can point to their wins as evidence that Americans voted them back in on an affordability agenda—and again insist that the subsidies be reinstated as a condition of continuing to fund the government.

 

That outcome could be particularly important for people who rely on ADAPs within Ryan White. The more expensive ACA plans become, the more likely that states that are already making hard choices about what (and whom) their ADAPs cover will stop covering premiums on ACA plans or will cap how much of those premiums they cover. The difference between, say, $500 and $1,000 that an individual person’s monthly ACA premium costs could also be the difference in whether their state’s ADAP will pick up the tab.

 

What’s the final takeaway?

 

Even if Democrats were to take both chambers of Congress, they almost surely won’t have the two-thirds majority to override a Trump veto on bills that reverse the many harmful measures the current GOP Congress has passed. 

 

However, on issues both specific to people with HIV, such as Ryan White funding, and those that affect broader populations—from healthcare to housing to reining in ICE—Democratic control of Congress would give the party more leverage during budget negotiations as well as more opportunity to oversee and investigate Trump administration actions.

 

That’s why the stakes are so high in the midterms. “They’re really important,” says Dawson. “Affordability issues are driving the midterms, and that includes healthcare.”

 

And, these experts caution, voters living with or without HIV shouldn’t be complacent about current polls showing Democrats have a promising chance of taking the House and even a slim chance of taking the Senate. “Polling has been incorrect many times,” notes Boykin. g